SCHEMBL3676046

SCHEMBL3676046

O=C(NCCCCc1ccccc1)c1ccc(N2CCN(C(=O)c3cccc4ccccc34)CC2)nc1.O=C(NCCc1cccc(Cl)c1)c1ccc(N2CCN(C(=O)Cc3ccc4ccccc4c3)CC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 6/20 0.54
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
DRD2 P14416 1/20 0.41
ADRA1A P35348 1/20 0.41
DRD3 P35462 1/20 0.41
TGM2 P21980 2/20 0.40
DCTPP1 Q9H773 1/20 0.40
SLC6A4 P31645 1/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5586271 0.92 SCD (0.46) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3669356 0.90 NPC1 (0.51) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3670665 0.89 SCD (0.62) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3676071 0.87 ALDH1A1 (0.53) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3669524 0.86 SCD (0.66) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3670648 0.85 ALDH1A1 (0.60) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3674006 0.84 SCD (0.73) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3677858 0.83 SCD (0.67) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3667710 0.83 SCD (0.57) SCDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3668336 0.80 SCD (0.59) SCDNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT SCD 10/4885NPC1 94/4885RAB9A 1717/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 SCD 1186/4885NPC1 31/4885RAB9A 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.